Bioxytran, Inc. (BIXT)

Bioxytran Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	2.14	2.67	1.16	2.2	0.72	1.63
Research & Development	0.62	1.15	0.98	2.01	0.54	-
Operating Expenses	2.77	3.83	2.14	4.21	1.27	1.63
Operating Income	-2.77	-3.83	-2.14	-4.21	-1.27	-1.63
Interest Expense	-	-0.54	-0.52	-0.31	-1.27	-0.23
EBT Excluding Unusual Items	-2.72	-4.37	-2.66	-4.53	-2.54	-1.86
Pretax Income	-2.72	-4.37	-2.66	-4.53	-2.54	-1.86
Earnings From Continuing Operations	-2.72	-4.37	-2.66	-4.53	-2.54	-1.86
Minority Interest in Earnings	0.02	0.09	0.19	0.5	0.06	-
Net Income	-2.7	-4.28	-2.46	-4.03	-2.48	-1.86
Net Income to Common	-2.7	-4.28	-2.46	-4.03	-2.48	-1.86
Shares Outstanding (Basic)	153	134	115	106	94	86
Shares Outstanding (Diluted)	153	134	115	106	94	86
Shares Change (YoY)	19.23%	16.35%	8.57%	13.07%	9.78%	0.58%
EPS (Basic)	-0.02	-0.03	-0.02	-0.04	-0.03	-0.02
EPS (Diluted)	-0.02	-0.03	-0.02	-0.04	-0.03	-0.02
EBITDA	-2.76	-3.82	-2.13	-	-	-
D&A For EBITDA	0.01	0.01	0	-	-	-
EBIT	-2.77	-3.83	-2.14	-4.21	-1.27	-1.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.